Simultaneous CRISPR/Cas9-induced double-strand breaks are lethal in models of pancreatic cancer
Authors:
- Selina Shiqing K. TehSTSelina Shiqing K. Teh
- Akhil KotwalAKAkhil Kotwal
- Alexis BennettABAlexis Bennett
- Eitan Halper-StrombergEHEitan Halper-Stromberg
- Laura MorsbergerLMLaura Morsberger
- Saum ZamaniSZSaum Zamani
- Yanan ShiYSYanan Shi
- Alyza SkaistASAlyza Skaist
- Qingfeng ZhuQZQingfeng Zhu
- Kirsten BowlandKBKirsten Bowland
- Hong LiangHLHong Liang
- Ralph H. HrubanRHRalph H. Hruban
Open Access
- 15 May 2026
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (10)
Abstract
While radiation is an effective oncologic therapy, killing cancer by inducing DNA double-strand breaks (DSBs), it lacks specificity for neoplastic cells. We have previously adapted the CRISPR/Cas9 gene-editing technology as a cancer-specific treatment modality targeting somatic mutations in pancreatic cancer (PC). However, its tumoricidal potential remains unclear, especially in comparison with therapeutic doses of radiation. Here, we demonstrate that CRISPR/Cas9-induced DSBs are more cytotoxic in PCs than a comparable number of radiation-induced DSBs. We observed more than 90% tumor growth inhibition by targeting 9 sites with cancer-specific sgRNAs. Through both bioinformatics and cytogenetics analyses, we found that CRISPR/Cas9-induced DSBs triggered ongoing chromosomal rearrangements, with 87% of structural variants not directly produced from the initial CRISPR/Cas9-induced DSBs, and chromosomal instability peaking before cell death. By comparing the cytotoxicity of CRISPR/Cas9- and radiation-induced DSBs, we demonstrated that the number of DSBs required to achieve equitoxic effects was approximately 3 times higher for radiation than CRISPR/Cas9. Finally, we showed that PC cells that had survived CRISPR/Cas9 targeting retained susceptibility to subsequent CRISPR/Cas9-induced DSBs at different genomic sites with more than 87% growth inhibition. Together, our data support the therapeutic potential of CRISPR/Cas9 as an anticancer strategy. The CRISPR-Cas9 system can be adapted into a cancer killing strategy by inducing precise and unrecoverable DNA damage.Keywords
All Related Versions
Funding Information
- National Institutes of Health (R21CA164592,P50CA62924)
- The Sol Goldman Pancreatic Cancer Research Center (The Sol Goldman Pancreatic Cancer Research Center)
- PanCan/AACR Innovation Award (PanCan/AACR Innovation Award)
- The Stringer Foundation (The STRINGER Foundation)
- Casimir H. Zgonina Family Endowment for Pancreatic Cancer Research (Casimir H. Zgonina Family Endowment for Pancreatic Cancer Research)
- Dennis Troper and Susan Wojcicki (Dennis Troper)
- Dennis Troper and Susan Wojcicki (Susan Wojcicki)
- Dick Knox/Cliff Minor Fund (Dick Knox/Cliff Minor Fund)
- Edward A. Goldsmith Pancreatic Cancer Research Fund (Edward A. Goldsmith Pancreatic Cancer Research Fund)
- Elaine Crispen Sawyer Endowment (Elaine Crispen Sawyer Endowment)
- Elaine T. Koehler Pancreatic Cancer Research Fund (Elaine T. Koehler Pancreatic Cancer Research Fund)
- Eve Stancik Memorial Fund (Eve Stancik Memorial Fund)
- George Rubis Endowment for Pancreatic Cancer Research (George Rubis Endowment for Pancreatic Cancer Research)
- Hilda Buchfeller Yost Young Investigator’s Fund (Hilda Buchfeller Yost Young Investigator’s Fund)
- James S. McFarland Endowment for Pancreatic Cancer Research (James S. McFarl)
- James S. McFarland Endowment for Pancreatic Cancer Research (Endowment for Pancreatic Cancer Research)
- John J. Lussier Pancreatic Cancer Research Fund (John J. Lussier Pancreatic Cancer Research Fund)
- Linda C. Talecki Gallbladder Cancer Research Fund (Linda C. Talecki Gallbladder Cancer Research Fund)
- Mary M. Graf Memorial Endowment Fund for Gallbladder Cancer (Mary M. Graf Memorial Endowment Fund for Gallbladder Cancer)
- Mary Lou Wootton Endowment (Mary Lou Wootton Endowment)
- Professor J. Mayo Greenberg and Dr. Samuel L. Slovin Endowment (Professor J. Mayo Greenberg)
- Professor J. Mayo Greenberg and Dr. Samuel L. Slovin Endowment (Dr. Samuel L. Slovin Endowment)
- Rawlings Family Pancreatic Cancer Research Fund (Rawlings Family Pancreatic Cancer Research Fund)
- National Cancer Institute CCSG (P30CA006973)
This publication has 75 references indexed in Scilit:
- Paradoxical Relationship between Chromosomal Instability and Survival Outcome in CancerCancer Research, 2011
- Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawalNature, 2010
- Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cellsProceedings of the National Academy of Sciences, 2009
- Roles of ATM and NBS1 in chromatin structure modulation and DNA double-strand break repairNature Cell Biology, 2007
- γ-H2AX in Cancer Cells: A Potential Biomarker for Cancer Diagnostics, Prediction and RecurrenceCell Cycle, 2006
- Endogenous expression of phosphorylated histone H2AX in tumors in relation to DNA double-strand breaks and genomic instabilityDNA Repair, 2006
- Radiation-induced DNA damage and delayed induced genomic instabilityOncogene, 2003
- DNA Amplification by Breakage/Fusion/Bridge Cycles Initiated by Spontaneous Telomere Loss in a Human Cancer Cell LineNeoplasia, 2002
- ACTION OF X-RAYS ON MAMMALIAN CELLSJournal of Experimental Medicine, 1956
- The Behavior in Successive Nuclear Divisions of a Chromosome Broken at MeiosisProceedings of the National Academy of Sciences, 1939